Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache

NCT05365880 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-11-13

No results posted yet for this study

Summary

Determine the effects of sphenopalatine ganglion (SPG) block in post-stroke headache.

Conditions

Interventions

DRUG

Liquid Lidocaine

The investigational treatment is 2 mL of aqueous 2% lidocaine.

DRUG

Placebo

The active placebo comparator will be provided to participant.

Sponsors & Collaborators

Principal Investigators

  • Adam H de Havenon, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2025-03-22
Completion
2025-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365880 on ClinicalTrials.gov